Unlike most lazy pumpers here have been jumping up and down about in terms of a GSK/HGSI sealed document really refers to Exhibit 10.1 - Novartis and HGSI JV and Co-promotion Agreement. Gives details on all the Sales Force and Costs associated with Calls and Obligations of making 50% of obligated calls and how they will account for the payments between the partners for Sales Calls. Primary, Secondary and Tertiary drug Calls and treatment thereof. Talks about breakup of the royalties between the two and Genentech and goes in the minutest details of the JV between HGSI and Novartis on Albuferon. Exhinit 10.5 - Deals with ABthrax. Based on what I have read, there is an additional payment in addition to the 163M already received for 20K doses sold to US Govt. (which reflects a discounted price) when the drug gets approved. When they mention they will close out the year with 350M-390M but didnt account for the 50M they spent on buying back the debt, I think the additional payment will be in excess of 50M as a result they keep harping on their ability to meet the financial goal of closing north of 350M. It still does not take into account milestone payments from NVS for Albuferon and milestone payments from GSK.
So, pump all you want but the highly confidential documents have nothing to do with GSK, you can still sell and get out now before it is too late. I hate to say I told you so, but I will tell you I told you so.